Nuvation Bio: Buy The Ibtrozi Launch (Rating Upgrade)

Nuvation Bio received a Buy rating upgrade driven by Ibtrozi's growing adoption in ROS1+ NSCLC. Ibtrozi's median response duration approaches 50 months, with first-line patient share exceeding 50%. A revised SOTP analysis values NUVB equity at $2.1 billion ($6.03/share), roughly 25% above current prices.